Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia
A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu Hospital, Shandong University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet the diagnostic criteria for immune thrombocytopenia.
- 18-50 years of age; gestational age over 32 weeks;
- No response to the treatment of glucocorticoids and / or intravenous immunoglobulin (a stable dose of glucocorticoid could be accepted);
- Platelet transfusion was not effective.
- Platlet count of the patients <30* 10^9/L and had the risk of bleeding or bleeding.
- No obvious abnormalities in liver and kidney function had (1.5 times higher than normal limit of the serum urea nitrogen, creatinine, serum transaminase and bilirubin );
- No severe cardiac and pulmonary dysfunction;
- No history of mental illness;
- Voluntarily signed written informed consent.
Exclusion Criteria:
- A history of serious allergies to biologics;
- The history of thrombosis;
- Thromboembolic or hemorrhagic disease;
- Patients who are deemed unsuitable for the study by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: experimental group
Accepting the treatment of rhTPO according platelet and bleeding condition
|
If platelet count <30×10^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10^9/L and 50×10^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count <30×10^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10^9/L and 50×10^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
Other Names:
|
|
ACTIVE_COMPARATOR: non-administered group
No rhTPO will be used.
If necessary, the patients will be given transfusion of platelets according to the their conditions.
|
according to the their conditions, use if necessary
|
|
NO_INTERVENTION: healthy control group
Healthy pregnant women and no use of any medicine。
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Platelet count during delivery
Time Frame: up to 2 years per subject
|
Platelet count during delivery will be assessed
|
up to 2 years per subject
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events in neonates
Time Frame: up to 2 years per subject
|
The number and frequency of therapy associated adverse events in neonates
|
up to 2 years per subject
|
|
platlet count of newborns
Time Frame: up to 42 days per newborn
|
Platelet counts of D1, 3, and 7 of newborns, extended to d42 if thrombocytopenia occurs.
|
up to 42 days per newborn
|
|
Adverse events in parturients
Time Frame: up to 2 years per subject
|
The number and frequency of therapy associated adverse events in parturients
|
up to 2 years per subject
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ming Hou,, Dr, Shandong University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
Other Study ID Numbers
Other Study ID Numbers
- rhTPO in pregnancy of ITP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.